Stereoselective pharmacokinetics of pantoprazole, a proton pump inhibitor, in extensive and poor metabolizers of S-mephenytoin

Clinical Pharmacology and Therapeutics

Volumn 69, Issue 3, 2001, Pages 108-113

  Tanaka, Makoto ^a,b,c,d   Ohkubo, Tadashi ^a,b,c,d   Otani, Koichi ^a,b,c,d   Suzuki, Akihito ^a,b,c,d   Kaneko, Sunao ^a,b,c,d   Sugawara, Kazunobu ^a,b,c,d   Ryokawa, Yuichi ^a,b,c,d   Ishizaki, Takashi ^a,b,c,d  

^a DAIICHI SANKYO CO   (Japan)

^b HIROSAKI UNIVERSITY HOSPITAL   (Japan)

^c YAMAGATA UNIVERSITY   (Japan)

^d KUMAMOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2C19; LANSOPRAZOLE; MEPHENYTOIN; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE;

AREA UNDER THE CURVE; ARTICLE; CONCENTRATION RESPONSE; DOSE RESPONSE; DRUG CLEARANCE; DRUG DISPOSITION; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG METABOLISM; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; HUMAN TISSUE; MALE; NORMAL HUMAN; PRIORITY JOURNAL; STEREOCHEMISTRY; STOMACH ACID SECRETION;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADMINISTRATION, ORAL; ADULT; ANTI-ULCER AGENTS; ANTICONVULSANTS; AREA UNDER CURVE; BENZIMIDAZOLES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HALF-LIFE; HUMANS; MALE; MEPHENYTOIN; METABOLIC CLEARANCE RATE; OMEPRAZOLE; STEREOISOMERISM; SULFOXIDES;

EID: 0035103370     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1067/mcp.2001.113723     Document Type: Article

References (23)

1. +)-ATPase inhibitor
2. Effect of repeated oral administration of BY 1023/SK&F 96022 - A new substituted benzimidazole derivative - On pentagastrin-stimulated gastric acid secretion and pharmacokinetics in man
3. Pharmacokinetics of pantoprazole following single intravenous and oral administration to healthy male subjects
4. Dose linearity of the pharmacokinetics of the new H+/K+-ATPase inhibitor pantoprazole after single intravenous administration
5. +-ATPase-inhibitor pantoprazole (BY 1023/SK&F96022) in healthy volunteers
6. Pantoprazole: A review of its pharmacological properties and therapeutic use in acid-related disorders
7. Pharmacokinetics and tolerance of pantoprazole, a proton pump inhibitor after single and multiple oral doses in healthy Japanese volunteers
8. Metabolic disposition of pantoprazole, a proton pump inhibitor, in relation to S-mephenytoin 4′-hydroxylation phenotype and genotype
9. Omeprazole: A comprehensive review
10. Lansoprazole, a review of its pharmacodynamic and pharmacokinetic properties and its therapeutic efficacy in acid-related disorders
11. Pharmacokinetic properties of E3810, a new proton pump inhibitor, in healthy male volunteers
12. Determination of R(+)- and S(-)-lansoprazole using chiral stationary-phase liquid chromatography and their enantioselective pharmacokinetics in humans
13. Enantioselective hydroxylation of omeprazole catalyzed by CYP2C19 in Swedish white subjects
14. Differential stereoselective pharmacokinetics of pantoprazole, a proton pump inhibitor in extensive and poor metabolizers of pantoprazole: A preliminary study
15. Direct determination of pantoprazole enantiomers in human serum by reversed-phase high-performance liquid chromatography using a cellulose-based chiral stationary phase and column-switching system as a sample cleanup procedure
16. TopFit: A PC-based pharmacokinetic/pharmacodynamic data analysis program
17. 14C-labelled pantoprazole to young healthy male volunteers
18. Disposition kinetics and metabolism of omeprazole in extensive and poor metabolizers of Smephenytoin 4′-hydroxylation recruited from an Oriental population
19. Polymorphic hydroxylation of Smephenytoin and omeprazole metabolism in Caucasian and Chinese subjects
20. Interphenotype differences in disposition and effect on gastrin levels of omeprazole: Suitability of omeprazole as a probe for CYP2C19
21. Pharmacokinetics of omeprazole (a substrate of CYP2C19) and comparison with two mutant alleles, CYP2C19m1 in exon 5 and CYP2C19m2 in exon 4, in Japanese subjects
22. Metabolic disposition of lansoprazole in relation to the S-mephenytoin 4′-hydroxylation phenotype status
23. Continuing development of acid pump inhibitors: Site of action of pantoprazole